Virtify Inc. has $15 million in new funding to support its work on compliance and management tools for the clinical trials market.
The Cambridge, Mass.-based firm launched six years ago and counts several pharmaceutical and biotechnology companies among its clients. The company debuted its Virtx software suite in June, 2009, touting it as the first secure, completely Web-based compliance program designed to work across multiple regulatory jurisdictions.
The $15 million Series A financing package was reported in securities documents filed Jan. 11. Virtify did not identify any of the eight investors participating in the round, although Robert Forlenza, managing partner at Boston-based Tudor Ventures, is a director at Virtify and the firm is also listed as a portfolio company on the Tudor website.
In addition to its operation in Cambridge, Virtify has offices in India, Bulgaria and the Philipines. The firm does not publicly report revenues or earnings.